Medpace Holdings, Inc. $MEDP Shares Sold by Blair William & Co. IL

Key Points

• Blair William & Co. IL reduced its stake in Medpace Holdings, Inc. by 75.3% during the second quarter, selling 25,146 shares and holding 8,269 shares valued at approximately $2.6 million.
• Medpace reported a 14.2% year-over-year revenue increase with revenue of $603.31 million and an EPS of $3.10 for the last quarter, surpassing analysts' expectations.
• Recent analyst recommendations show a shift in sentiment, with two analysts rating the stock as Buy, while others have lowered their ratings, resulting in an average target price of $424.10.

Blair William & Co. IL trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 75.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,269 shares of the company's stock after selling 25,146 shares during the period. Blair William & Co. IL's holdings in Medpace were worth $2,595,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Medpace by 37.1% in the first quarter. GAMMA Investing LLC now owns 307 shares of the company's stock valued at $94,000 after purchasing an additional 83 shares during the period. Inspire Investing LLC acquired a new stake in shares of Medpace in the first quarter worth approximately $2,059,000. Truist Financial Corp boosted its stake in shares of Medpace by 10.2% in the second quarter. Truist Financial Corp now owns 12,898 shares of the company's stock worth $4,048,000 after acquiring an additional 1,197 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Medpace by 10.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,182 shares of the company's stock worth $371,000 after acquiring an additional 111 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in shares of Medpace by 7.6% in the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company's stock worth $6,696,000 after acquiring an additional 1,560 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

MEDP opened at $516.93 on Wednesday. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $547.15. The company has a market cap of $14.52 billion, a P/E ratio of 38.43, a PEG ratio of 3.31 and a beta of 1.40. The business's 50-day simple moving average is $486.83 and its 200-day simple moving average is $377.81.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business's revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other news, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 36,196 shares of the business's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the transaction, the chief executive officer directly owned 925,799 shares of the company's stock, valued at approximately $440,587,744.10. This trade represents a 3.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MEDP. Truist Financial lifted their price target on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Mizuho boosted their price objective on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Rothschild & Co Redburn lowered Medpace from a "buy" rating to a "neutral" rating and boosted their price objective for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Zacks Research lowered Medpace from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 22nd. Finally, Jefferies Financial Group boosted their price objective on Medpace from $400.00 to $450.00 and gave the company a "hold" rating in a report on Tuesday, September 9th. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Medpace presently has an average rating of "Reduce" and an average target price of $424.10.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.